Pregabalina Cinfa is relevant when supportive symptom management is appropriate across several therapeutic domains. Its main therapeutic utility is associated with symptomatic relief across key domains, which include addressing chronic pain caused by nerve damage, supporting the management of partial-onset seizures, and helping with symptoms of Generalized Anxiety Disorder (GAD).

Relief from Chronic Neuropathic Pain

This medication is applied in addressing symptoms related to increased neurological or muscular activity, relevant in conditions like diabetic neuropathy or postherpetic neuralgia. It helps address symptom clusters that may become intense or disruptive, such as burning, shooting, or stabbing sensations, and supports patients during episodes of heightened discomfort from persistent pain. It is helpful in situations where symptoms related to heightened physiological activity interfere with daily functioning, and may assist with maintaining functional stability during symptomatic periods.

Adjunctive Therapy for Partial-Onset Seizures

Pregabalina Cinfa is commonly used across conditions characterized by episodic or fluctuating manifestations, playing a role in managing partial-onset seizures as an add-on treatment in adults and children (starting from one month of age). It is relevant when supportive symptom management is appropriate for symptoms associated with acute or episodic changes, and helps ease the overall seizure burden.

---

Quick Fact: Relief for Neuropathic Pain
Symptom Type: Burning, shooting, electric-shock sensations
Condition Context: Diabetic peripheral neuropathy, postherpetic neuralgia
Patient Benefit: Helps maintain functional stability

Regulatory References

1. European Medicines Agency

Official Eligibility Profile for Pregabalina Cinfa

Eligibility to use Pregabalina Cinfa is defined by regulatory authorities based on specific patient populations, age, and existing medical conditions.

Absolute Non-Eligibility

The medicine is contraindicated and must not be used by patients with known hypersensitivity to the active substance, Pregabalin, or any of the inactive ingredients (excipients).

Age and Indication Restrictions

Population	Eligibility Status (by Indication)
Adults (ge 18 years)	Approved for all licensed uses (neuropathic pain, GAD, and seizures).
Children/Adolescents (Under 18)	Not recommended for neuropathic pain or Generalized Anxiety Disorder (GAD).
Infants/Children (ge 1 month)	Approved only for adjunctive therapy for partial-onset seizures.
Older Adults (ge 65 years)	Eligible, but may require dose adjustment due to age-related kidney function decline.

Conditional Use and Restrictions

Use is highly restricted for certain groups. Patients with impaired renal function require a dose adjustment based on their creatinine clearance. Additionally, the medicine is not recommended during pregnancy and breastfeeding. Special caution is required for patients with a history of substance abuse or pre-existing cardiovascular compromise, as defined in regulatory labeling.

Interactions with other medicines and products

The official regulatory profile for Pregabalina Cinfa is characterized by an absence of clinically relevant pharmacokinetic interference. Regulatory documents state that pregabalin is negligibly metabolized and does not inhibit or induce major CYP450 enzymes, meaning it is not documented to alter the plasma concentration or clearance of most co-administered medicines.

The most significant documented interactions are pharmacodynamic, involving additive effects on the central nervous system (CNS). Co-administration with CNS depressants, including opioid analgesics and benzodiazepines, increases the risk of potentiation of side effects such as severe somnolence, dizziness, and life-threatening respiratory depression. Caution is also officially required when co-administering with thiazolidinedione antidiabetics due to an increased risk of peripheral edema and weight gain, and with ACE inhibitors due to an increased risk of angioedema.

Consumption of alcohol or use of sedating herbal products is documented to potentiate CNS side effects. The immediate-release capsule can be taken with or without food. Population-specific notes state that the elderly and patients with underlying respiratory or renal impairment are at a higher risk for severe respiratory depression when combined with CNS depressants.

The mechanism of action for Pregabalina Cinfa (Pregabalin) centers on its ability to modulate neural signal transmission by targeting specific proteins on nerve endings within the central nervous system.

---

Targeting the Alpha-2-Delta Protein

Pregabalin acts as a high-affinity ligand that binds to the alpha-2-delta (alpha2-delta) subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs). This binding modulates the channel's function, leading to a regulated reduction in the influx of calcium ions ( Ca^2+) into the nerve terminal. The binding exhibits increased activity in settings of pathological hyperexcitability.

---

Dampening Excitatory Chemical Release

The diminished influx of calcium ions reduces the rate of exocytosis, resulting in a decreased release of key excitatory neurotransmitters into the synapse, notably Glutamate and Substance P. This action regulates the available chemical messengers for synaptic transmission.

---

Modulating Neuronal Hyperexcitability

By reducing the excessive release of these excitatory chemicals, the drug exerts a central dampening effect, which modulates neuronal hyperexcitability—a state characterized by heightened neuronal activity. This mechanism leads to an altered, dampened pattern of nerve impulse transmission throughout the nervous system.

How Pregabalina Cinfa is Used: Official Administration Guidelines

Pregabalina Cinfa is administered only by the oral route (by mouth) and is available as hard capsules or an oral solution. It may be taken with or without food.

Standard Dosing and Schedule

Treatment typically begins with a total daily dose of 150 mg, which is divided and taken in two (BID) or three (TID) separate doses per day. The official dose range for adult patients with normal kidney function is 150 mg to 600 mg per day.

• Dose Titration: Dosage increases, if required, are implemented gradually. The dose is typically increased to 300 mg/day after a minimum interval of three to seven days and may be raised up to the maximum dose after further weekly adjustments.
• Maximum Dose: The maximum daily dose for most approved adult indications (e.g., epilepsy, neuropathic pain) is 600 mg per day. For some conditions like diabetic peripheral neuropathy, the maximum recommended dose may be restricted to 300 mg per day.

Special Administration Rules

Renal Function (Kidney Impairment): Pregabalin is primarily eliminated by the kidneys. Therefore, a mandatory dose adjustment is required for patients with reduced renal function. The total daily dose must be individualized based on creatinine clearance. Patients undergoing haemodialysis require a single supplementary dose immediately following the 4-hour procedure to replace the drug removed.

Stopping Treatment: If treatment with this medicine is to be discontinued, the dose must be gradually reduced over a minimum period of one week, regardless of the length of treatment or the condition being managed.

Research Evidence / Overview of Studies for Pregabalina Cinfa

This section provides a factual overview of the clinical research that has been conducted on the active ingredient, pregabalin, focusing on what types of studies exist and what they were designed to measure. This is a non-advisory summary intended to help describe the broader evidence landscape.

---

Evidence for Use in Peripheral Neuropathic Pain

Research exploring outcomes related to symptom intensity (nerve pain) was studied for in multiple short-term, randomized controlled trials (RCTs) used to explore outcomes compared to a placebo. These studies primarily examined adults with pain caused by Diabetic Peripheral Neuropathy (DPN) and Postherpetic Neuralgia (PHN). In these trials, researchers primarily monitored patient-reported outcomes describing perceived discomfort, such as changes in standardized scales used to rate pain intensity.

Studies monitored and reported the proportion of patients in the different groups who reached pre-defined thresholds of measured change on scales evaluating symptom intensity over short periods. What remains uncertain is the long-term data from controlled settings, as follow-up durations were limited in the primary efficacy studies. While these findings describe group patterns, research does not determine whether an individual will respond similarly.

---

Evidence for Use as Adjunctive Therapy for Partial-Onset Seizures

The compound was evaluated in settings involving partial-onset seizures, which are conditions characterized by fluctuating or episodic manifestations. The primary research consists of short-term randomized controlled trials (RCTs) where the compound was studied alongside existing anti-epileptic drugs. Researchers explored outcomes describing episodic or acute changes by monitoring the frequency of seizures over defined time intervals.

Studies monitored and reported measurements of seizure frequency change over the 11 to 14-week study duration. The evidence for use in pediatric populations (starting from one month of age) was developed using specialized studies that examined how the compound is processed by the body to contextualize findings across age groups. Data for certain groups remain insufficient, particularly concerning the use of the medicine as a sole treatment (monotherapy).

---

What is Still Uncertain About the Study Landscape

The long-term effects of the compound on functional outcomes reflecting daily functioning are not fully established, as most RCTs focused on short-term symptom scales. Comparative evidence is lacking for many direct comparisons against other standard treatments for these indications. Furthermore, the evidence base for less common subtypes, such as central neuropathic pain, is limited. The research provides context but not individual predictions.

Key Studies & References

1. NICE Guideline: Neuropathic pain in non-specialist settings: pharmacological management

Common questions about Pregabalina Cinfa (FAQ)

Q: How should I dispose of unused or expired Pregabalina Cinfa?

Unused or expired Pregabalina Cinfa should be disposed of in a way that prevents accidental misuse or ingestion. Official patient information often recommends using an authorized drug take-back program if one is available in your area. As this medicine is classified as a controlled substance, it is important to check and follow any specific local regulations for controlled substance disposal.

Q: How long must I wait before increasing my dose?

Dosage adjustments are implemented gradually over time, following administration guidelines. Official administration guidelines indicate that dosage increases are typically considered after a minimum interval of three to seven days, followed by further weekly adjustments as determined by the prescribing healthcare professional.

Q: Does Pregabalina Cinfa affect the concentration of other medications I'm taking?

Regulatory documents state that Pregabalina Cinfa is not documented to affect the plasma concentration of most other medicines. This is because the drug is negligibly metabolized and does not typically interfere with the body's systems that process most other medicines.

Q: What are the most common side effects of the medicine?

Official reports from clinical trials indicate that the most commonly observed side effects are dizziness and somnolence (sleepiness). These effects are categorized as 'Very Common,' meaning they have been observed in at least 1 in 10 people during clinical studies, but their occurrence is not guaranteed for any individual.

Q: Are there any food restrictions while taking Pregabalina Cinfa?

The immediate-release capsules can be taken with or without food. Regulatory information generally does not list specific food restrictions. However, official documentation indicates that the use of alcohol may increase the risk of central nervous system side effects, such as severe sleepiness.

Q: What are the ingredients in the hard capsules?

The product contains the active ingredient, pregabalin. In addition, the hard capsules contain inactive ingredients, also known as excipients, to form the medicine. A full list of all active and inactive ingredients can be found in the official Patient Information Leaflet or the Prescribing Information document.

Q: How should I store the oral solution?

The oral solution, similar to the capsules, must be stored out of the sight and reach of children. The specific temperature and handling instructions should be followed as detailed in the official product labeling or Patient Information Leaflet.

Official Storage and Disposal Instructions

Storage Requirements

Pregabalina hard capsules generally do not require any special temperature storage conditions and have a typical shelf-life of three years when kept in the original, unopened package. The medicine must be stored out of the sight and reach of children and, where mandated by regulation, should be kept locked up due to its classification as a centrally acting substance.

Packaging and Handling

The product should be stored in its original container, such as the blister pack or HDPE bottle, to maintain stability. The container is often equipped with child-resistant closures to support safety requirements.

Disposal Guidelines

Unused or expired Pregabalina must be disposed of in accordance with local requirements for waste medicinal products. This often involves using an authorized drug take-back program or following specific local controlled substance disposal instructions to minimize environmental impact and prevent accidental ingestion.